Publication
Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma
In primary human T cells and patient samples, pharmacologic HIF-2α inhibition with belzutifan preserved proliferation, cytokine production, cytotoxicity, and activation states, supporting its immunologic safety in clear cell renal cell carcinoma.
Citation
Madsen KN, Kashima S, Soulati H, Wirth L, Ito K, Yochum ZA, Moritz V, Walker J, Machaalani M, Ghali F, Kenney P, Adeniran A, Hurwitz M, Choueiri TK, Braun DA. Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma. J Clin Invest. 2026 Oct 6:e204613. doi: 10.1172/JCI204613.